The ability of safinamide to impact some non-motor symptoms may represent the most promising & distinctive feature of this compound

A European delphi consensus on safinamide in the treatment pathway of #Parkinsons, from

@KRayChaudhuri1

& colleagues; "The ability of safinamide to impact some non-motor symptoms may represent the most promising & distinctive feature of this compound"

nature.com/articles/s41531-...

twitter.com/ScienceofPD/sta...

[CaseyInsights]

Looks like a treatment well worth exploring, even for those within the five year diagnostic time frame.

[CaseyInsights]

....Of note: Among MAO-B inhibitors, safinamide has a dual-mechanism of action since it is able to inhibit (a) MAO-B, potentiating dopaminergic transmission and (b) glutamate release by blocking voltage-dependent sodium channels and modulating calcium channels

And there was almost total agreement among movement specialist that the glutamatergic pathway is involved in the aetiopathogenesis of Parkinsons disease..